Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Common Stock

Last Annual Value

4.00K

3-Year CAGR

10%

5-Year CAGR

%

10-Year CAGR

%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Common Stock

SERA · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
4.00K
10.1%5.9%N/A 
445.00K
1.6%1.4%N/A
42.00K
6.3%4.3%3.1%
91.88K
79.2%41.9%N/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
9.86K
-1.8%-0.3%N/A
130.00K
22.3%13.1%20.8%
369.21M
6.0%7.9%23.2%
29.00K
60.6%-30.7%27.3%
364.00K
0.3%6.1%8.2%
131.00K
46.1%30.2%N/A
59.34K
105.9%67.3%15.1%
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245